AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00888459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo NRT
Description: Placebo nicotine lozenges
Study NCT03431974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LD-Aminopterin oral capsule
Description: anti-folate treatment
Study NCT03431974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Microcrystalline filled capsule to mimic capsule containing aminopterin tablets
Study NCT03322384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epacadostat
Description: Epacadostat will be administered orally, in pill form, twice daily until disease progression.
Study NCT03322384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101
Description: Four milligrams of SD-101 will be delivered into the treatment lesion by intralesional injection on days 1, 8, 15, 22, and 29.
Study NCT03322384 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will be delivered to the treatment lesion during the first week of ERS therapy.
Study NCT03566264 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study NCT02337140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker SORIN Group KORA DR
Study NCT02337140 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transcatheter aortic valve implantation (TAVI)
Study NCT02337140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcatheter aortic valve implantation (TAVI)
Study NCT00441350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OM 40
Description: Initially patients were to be treated with Olmesartanmedoxomil (OM)40 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/12.5 mg and responders remained on the previous therapy for further 8 weeks.
Study NCT00441350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OM/HCTZ 40/12.5
Description: Initially patients were to be treated with Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/25 mg and responders remained on the previous therapy for further 8 weeks.
Study NCT01772264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: titration from 150mg BID to 450mg BID
Study NCT01772264 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo
Study NCT01687348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine aguettant
Study NCT01660464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT Based Self-help Workbook + Counseling Telepho
Description: Over a period of 12 months parents work through 8 self-help booklets and additionally receive 14 counseling telephone calls. The intervention has a cognitive-behavioral foundation. Primary purpose of counseling telephone calls is to clarify contents of the booklets and support parents in managing their homework assignments accompanied with each booklet.
Study NCT02138136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: 12 or 24 mcg soft capsules for oral administration
Study NCT02563717 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T-piece used for respiratory support (several manufacturers)
Description: Infants will receive support by a standard T-piece resuscitator system (manufacturer not dictated in protocol). Apart from the system used for respiratory support all patients will receive standard care (specified in management protocol)
Study NCT03008733 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electro myography surface nerves
Description: Electro myography surface nerves
Study NCT01002053 — intervention group
Intervention type: PROCEDURE
Intervention: Nerve conduction study and Ultrasound of the PTN
Description: Nerve Conduction studies and ultrasound of PTN will be performed to the patient before the operation and 8 weeks postoperatively.
Study NCT01925651 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: No Bolus
Description: no bolus use
Study NCT01925651 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Alternate Bolus
Description: 0.5cm bolus use in alternate days
Study NCT01925651 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Continuous Bolus
Description: 0.5 cm bolus use in continuous days
Study NCT00804375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2PX
Description: cutaneous solution to be applied twice daily for 84 days
Study NCT00804375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: cutaneous solution to be applied twice daily for 84 days
Study NCT02767856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IO-therapy Glasses
Study NCT02767856 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IO-therapy Glasses
Study NCT04799184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.25% with epinephrine 5 ug/ml
Description: The block will be performed under ultrasound vision at T5 level, with the patient seated.~Once the ultrasound image is achieved, a 100 mm, 20 G Stimuplex needle will be punctured and a solution of levobupivacaine 0.25% with epinephrine 5 ug / ml until completing a volume of 20 ml in fractional form.
Study NCT04799184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine 0.25% without epinephrine 5 ug/ml
Description: The block will be performed under ultrasound vision at T5 level, with the patient seated.~Once the ultrasound image is achieved, a 100 mm, 20 G Stimuplex needle will be punctured and a solution of levobupivacaine 0.25% without epinephrine 5 ug / ml until completing a volume of 20 ml in fractional form.
Study NCT02097433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: A single 45 mg oral dose of Dacomitinib will be administered under fasted conditions to healthy Chinese volunteers
Study NCT02892838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile bearing knee system for total knee arthroplasty
Study NCT02892838 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fixed bearing total knee prosthesis
Study NCT03537352 — intervention group
Intervention type: PROCEDURE
Intervention: Any appropriate surgical treatment
Description: Any appropriate surgical treatment for the management of patient's current disorder
Study NCT03537352 — intervention group
Intervention type: DRUG
Intervention: Any appropriate drug or non-drug treatment excluding surgery
Description: Any appropriate drug or non-drug treatment excluding surgery for the management of patient's current disorder
Study NCT01326117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil
Description: 7 days of Cialis for Daily Use (5mg)
Study NCT01608399 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive therapy
Description: Metacognitive therapy, 10 weekly sessions of 45-60 minutes duration each
Study NCT01365377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: booklet deliverance and use in the process of daily information
Description: The brochure shows with text and pictures the day-living of the ICU ; Medical and para-medical staff and organization, the devices, complications and treatment
Study NCT01464788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Argatroban
Description: 100 micrograms/kilogram bolus, followed by 1 microgram/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
Study NCT01464788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Argatroban
Description: 100 micrograms/kilogram bolus, followed by 3 micrograms/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
Study NCT01464788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rt-PA (alteplase)
Description: rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
Study NCT01464788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rt-PA (alteplase)
Description: rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
Study NCT03831308 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: clinical and physical assessment
Description: information will be collected on fitness status, lifestyle, cognitive and psychological status, bone's health and quality of life
Study NCT01811355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mexiletine
Description: Sodium channel blocker
Study NCT01811355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05239377 — intervention group
Intervention type: OTHER
Intervention: IntelliSpace Precision Medicine Multidisciplinary Team Orchestrator
Description: Digital decision support
Study NCT02557412 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure
Description: Treatment with nasal CPAP. Treatment begins with an empirical pressure of 8 cmH2O and in a period of three weeks, the pressure is adjusted by automatic titration with AutoSet II (ResMed) device.
Study NCT02557412 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive lifestyle intervention
Description: Specific alimentary plan (carbohydrates: 40-45%; fats: 25-35% \[saturated fats \<7% monounsaturated fats up to 20% and polyunsaturated fats \<10% \] and proteins: 15-20%) and recommendation to increase daily physical activity, setting a target walking 10,000 steps a day. The patients will be provided with a pedometer and will asked to fill out a form with the steps that they walked each day. At each visit, the distance walked will be reviewed and the target set will be remarked.
Study NCT02557412 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional treatment
Description: Hygiene and diet recommendations on sleep
Study NCT00218920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training
Description: a strength training regime of 4 series with 5 repetitions each, at approximately 90% of 1 repetition maximum (RM), in a leg press apparatus to develop maximal strength mainly from neural adaptation with minimal weight gain due to muscular hypertrophy.
Study NCT00218920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: continuous moderate-intensity aerobic training
Description: The moderate-intensity group walked continuously for 47 min at 60-70% of maximum heart rate (HRmax) to ensure that the training protocols were isocaloric.
Study NCT00218920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high-intensity interval aerobic training
Description: High-intensity training consisted of a 10 min warm-up period at 50-60% of HRmax \[maximal HR (heart rate)\], followed by 4×4-min intervals at 85-95% of HRmax with 3 min active breaks in between the intervals, consisting of walking or jogging at 50-60% of HRmax. The exercise session was terminated by a 5 min cool-down period.
Study NCT02558556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Fluorescence Imaging System (Karl Storz)
Description: The Laparoscopic Fluorescence Imaging System (incl. laparoscope, light source, light cable) will supply the needs for near-infrared fluorescence imaging with ICG. The hypothesis is that this device will help in visualizing the anatomical structures such as the common bile duct, which are hard to visualize in white light due to the surrounding tissues.
Study NCT02558556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Indocyanine Green will be injected intravenously as a contrast agent for the use of the Laparoscopic Fluorescence Imaging System.
Study NCT01736254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Study NCT01736254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Study NCT04172753 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy on the MR-Linac
Description: Radiotherapy is performed on the 1.5 T MR Linac
Study NCT00158782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Lapatinib is an oral, reversible, tyrosine kinase inhibitor of both epidermal growth factor receptor-1 (ErbB1) and ErbB2.
Study NCT04134793 — intervention group
Intervention type: PROCEDURE
Intervention: radiofrequency ablation
Description: bipolar radiofrequency ablation by ablation forceps
Study NCT02543125 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIPPV
Description: For infants in the NIPPV-group who failNIPPV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician.
Study NCT02543125 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NHFOV
Description: For infants in the NHFOV-group who failNHFOV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician.
Study NCT02563717 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: New system used for respiratory support
Description: Infants will receive support by the new system (manufactured by Inspiration Healthcare, UK). Apart from the system used for respiratory support all patients will receive standard care (specified in management protocol)
Study NCT01311557 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed
Description: 0.5 mL, Intramuscular
Study NCT02104336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-743
Description: EPI-743 is the quinone oxidation product of alpha-tocotrienol
Study NCT01475006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 595
Description: AMG 595 is an antibody drug conjugate that binds to EGFRvIII.
Study NCT04566705 — intervention group
Intervention type: OTHER
Intervention: Risks factors, maternal and neonatal outcomes/complications
Description: Risks factors, maternal and neonatal outcomes/complications
Study NCT06332001 — intervention group
Intervention type: OTHER
Intervention: Experimental Group
Description: Listening of music of patient's choice during WB-MRI
Study NCT06332001 — intervention group
Intervention type: OTHER
Intervention: Control Group
Description: Standard care condition during WB-MRI
Study NCT03725865 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Induction of neural stem cells
Description: Brain injection iNSC
Study NCT00223353 — intervention group
Intervention type: OTHER
Intervention: Prosthetics, Orthotics and Physical Therapy
Description: Gait Analysis.
Study NCT00503711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: 100 mg every other day, 100mg once daily
Study NCT00503711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg
Description: 300mg once daily
Study NCT04172753 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Imaging on the MR Linac
Description: Only imaging performed on the MR Linac
Study NCT01328236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: INDUCTION THERAPY: 1.3 mg/m2, IV (in the vein) on day 1， 4， 8， 11 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.~MAINTENANCE THERAPY: 1.3 mg/m2, IV (in the vein) on day 1， 4， 8， 11 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops.
Study NCT01328236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome doxorubicin
Description: INDUCTION THERAPY: 30 mg/m2, IV (in the vein) on day 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
Study NCT01328236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: INDUCTION THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.~MAINTENANCE THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops.
Study NCT01707368 — intervention group
Intervention type: DRUG
Intervention: Daivobet® Gel
Description: Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
Study NCT03923530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: Eplerenone 50 mg daily
Study NCT02728752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octagam 10%
Description: Patients to be treated with Octagam 10%
Study NCT02728752 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients to be treated with a Placebo
Study NCT01668693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERA (Endometrial Receptivity Array)
Description: The diagnostic tool ERA will be performed on all of the patients in order to allocate them in the group Receptive or Non Receptive and to predict the number of days of Progesterone administration necesary to obtain the Receptive prediction.
Study NCT01668693 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ERA (Endometrial Receptivity Array)
Description: The diagnostic tool ERA will be performed on all of the patients in order to allocate them in the group Receptive or Non Receptive and to predict the number of days of Progesterone administration necesary to obtain the Receptive prediction.
Study NCT01668693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Embryo Transfer
Description: When the ERA indicates receptivity, the patient will undergo the embryo transfer on the day indicated by the diagnostic tool.
Study NCT01668693 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Embryo Transfer
Description: When the ERA indicates receptivity, the patient will undergo the embryo transfer on the day indicated by the diagnostic tool.
Study NCT01668693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Second ERA
Description: A second ERA will be performed to confirm receptivity after further administration of Progesterone.
Study NCT00511992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Initial Treatment Bevacizumab 15mg/kg Day 1 IV every 21 days x 5 cycles (beginning with cycle 2)~Consolidation Treatment:~Avastin 15mg/kg IV every 21 days x 12 cycles
Study NCT00511992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 135mg/m2 IV Day 1 every 21 days x 6 cycles
Study NCT00511992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m2 IP day 2 every 21 days x 6 cycles
Study NCT00975286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.
Study NCT00975286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.
Study NCT00975286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: Dose to be adjusted to maintain a fasting SMPG between 100 and 80 mg/dL (5.6 and 4.4 mmol/L), inclusive.
Study NCT00975286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin glargine
Description: Dose to be adjusted to maintain a fasting SMPG between 100 and 80 mg/dL (5.6 and 4.4 mmol/L), inclusive.
Study NCT00975286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen auto-injector
Description: Lantus® SoloStar® OptiClik®
Study NCT00975286 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pen auto-injector
Description: Lantus® SoloStar® OptiClik®
Study NCT00975286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
Study NCT00975286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
Study NCT02034916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talazoparib
Study NCT00975286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiazolidinedione (TZD)
Description: TZD (either rosiglitazone or pioglitazone) if given, to be continued at stable dose up to Week 24.
Study NCT00975286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Thiazolidinedione (TZD)
Description: TZD (either rosiglitazone or pioglitazone) if given, to be continued at stable dose up to Week 24.
Study NCT02099604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin
Description: Vitamin D ARM: 28000UI/week during 4 weeks (lead in phase) then 28000 UI/week associated with PegIFN/RBV during 48 weeks
Study NCT04087356 — intervention group
Intervention type: GENETIC
Intervention: Blood draw
Description: Blood samples are collected for genetic analysis, looking specifically at serum lipids and the inflammatory biomarker hs-CRP.